Carsten Goessl - Concepedia

Author

Carsten Goessl

Institut Gustave Roussy

Also Known As

C Goessl, C. D. Goessl, C. Goessl, C. Goeßl, CARSTEN GOESSL, Carsten Dietrich Goessl, Carsten Goessl

144

Publications

14.4K

Citations

H-Index

Concepts

All Affiliations

Institut Gustave Roussy Freie Universität Berlin AstraZeneca (United States)AstraZeneca (United Kingdom)Amgen (United States)

About

Carsten Goessl is an author at Institut Gustave Roussy specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	37	4.8K
2	Health Sciences	10	10	290
3	Social Sciences	2	2	107
4	Engineering	1	1	276
5	Allergy	1	1	76

Carsten Goessl

Publications

13.9K

Citations

H-Index

Page 1

	Year	Citations
Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus, New England Journal of Medicine	2017	3.1K
Olaparib for Metastatic Castration-Resistant Prostate Cancer Johann S. de Bono, Joaquı́n Mateo, Karim Fizazi, New England Journal of Medicine	2020	2.1K
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Karim Fizazi, Michael A. Carducci, Matthew R. Smith, The Lancet UrologySurgical OncologyMedicineCancer ManagementDouble-blind Study	2011	1.9K
Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer Matthew Smith, Blair Egerdie, Narciso Hernández Toriz, New England Journal of Medicine	2009	1.1K
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial Matthew R. Smith, Fred Saad, Robert E. Coleman, The Lancet UrologyOncologyGenitourinary CancerCastration-resistant Prostate CancerCancer Treatment	2011	792
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer Mark E. Robson, Nadine Tung, Pierfranco Conté, Annals of Oncology	2019	725
Zoledronic Acid Significantly Reduces Skeletal Complications Compared With Placebo in Japanese Women With Bone Metastases From Breast Cancer: A Randomized, Placebo-Controlled Trial Norio Kohno, Kenjiro Aogi, Hironobu Minami, Journal of Clinical Oncology	2005	545
Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate Cancer Matthew R. Smith, Fairooz F. Kabbinavar, Fred Saad, Journal of Clinical Oncology	2005	493
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial Noel W. Clarke, Paweł Wiechno, B. Yа. Alekseev, The Lancet Oncology UrologyOncologyGenitourinary CancerMedicinePharmacotherapy	2018	405
Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Carsten Goessl, Hans Krause, Markus Müller, PubMed EngineeringDna AnalysisMolecular BiologyPathologyNucleic Acid Amplification Test	2000	276

Page 1